News
ECOR
5.65
+1.25%
0.07
Indivior PLC (INDV) Q1 Earnings and Revenues Lag Estimates
NASDAQ · 17h ago
Weekly Report: what happened at ECOR last week (0415-0419)?
Weekly Report · 3d ago
Weekly Report: what happened at ECOR last week (0408-0412)?
Weekly Report · 04/15 11:41
Weekly Report: what happened at ECOR last week (0401-0405)?
Weekly Report · 04/08 11:47
electroCore Announces the Launch of Truvaga Plus® for General Wellness
Barchart · 04/08 07:30
electroCore Expands Intellectual Property Portfolio With Two New Patents, "No. 11,944,815" And "No. 11,944,807"
ElectroCore, Inc. Has received two patents from the U.S. Patent and Trademark Office. The two patents relate to electroCore's non-invasive vagus nerve stimulation technology. ElectroCore is a commercial-stage bioelectronic medicine and wellness company.
Benzinga · 04/02 12:18
Weekly Report: what happened at ECOR last week (0325-0329)?
Weekly Report · 04/01 11:43
Weekly Report: what happened at ECOR last week (0318-0322)?
Weekly Report · 03/25 11:47
Weekly Report: what happened at ECOR last week (0311-0315)?
Weekly Report · 03/18 11:45
Analysts Are Bullish on These Healthcare Stocks: Electrocore (ECOR), Viking Therapeutics (VKTX)
TipRanks · 03/15 11:40
Electrocore’s Battle with Cyber Threats: Protecting Sensitive Data Amidst Rising Security Risks
TipRanks · 03/15 06:02
Electrocore’s Growth Trajectory: A Buy Rating with Promising Prospects
TipRanks · 03/14 10:27
ElectroCore, Inc. (ECOR) Reports Q4 Loss, Lags Revenue Estimates
NASDAQ · 03/13 21:25
electroCore Q4 2023 GAAP EPS $(0.61), Inline, Sales $5.191M Beat $4.967M Estimate
ElectroCore (NASDAQ:ECOR) reported quarterly losses of $0.61 per share. The company reported quarterly sales of $5.191 million which beat the analyst consensus estimate of $4.967 million. ElectroCore also reported a 102.77 percent increase in sales over the same period.
Benzinga · 03/13 20:07
BRIEF-electroCore Q4 Net Income USD -4.032 Million
Reuters · 03/13 20:05
*electroCore 4Q Sales $5.19M >ECOR
Dow Jones · 03/13 20:05
Earnings Scheduled For March 13, 2024
Sangamo Therapeutics is expected to report earnings for its fourth quarter. Dollar Tree is estimated to report quarterly earnings at $2.65 per share on revenue of $8.67 billion. Other companies reporting before the bell and after the bell include i-80 Gold and Optical Cable.
Benzinga · 03/13 10:15
Notable earnings after Wednesday's close
Major earnings expected after the bell on Wednesday include: UiPath, Lennar and GrowGeneration Corp. Other earnings slated for release after the close of business on Wednesday. For the full earnings season calendar, see Seeking Alpha's earnings calendar. Earnings after Wednesday's close.
Seeking Alpha · 03/12 21:35
ElectroCore Q4 2023 Earnings Preview
ElectroCore is scheduled to announce Q4 earnings results on Wednesday, March 13th. The consensus EPS Estimate is -$0.63 and the consensus revenue estimate is $5.02M. ECOR has beaten revenue estimates 100% of the time in the last year.
Seeking Alpha · 03/12 21:35
Weekly Report: what happened at ECOR last week (0304-0308)?
Weekly Report · 03/11 11:41
More
Webull provides a variety of real-time ECOR stock news. You can receive the latest news about Electrocore through multiple platforms. This information may help you make smarter investment decisions.
About ECOR
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company. It provides non-invasive vagus nerve stimulation (nVNS) technology platform. The Company’s product categories include Handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headache, and Handheld, personal use consumer products utilizing nVNS technology to promote general wellness and human performance. Its products include gammaCore, Truvaga and TAC-STIM. Its gammaCore Sapphire, is a prescription medical device that is used for a variety of primary headache conditions. Its Truvaga is a personal use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com. The Company’s TAC-STIM product is not a medical device and is not intended to diagnose, cure, mitigate, prevent, or treat a disease or condition.